Our board of directors consists of seven members, Messrs. Lynch, Carragher, Donnelly, Maher, Thornton and Drs. McKenna and Manuso. Our directors hold office until the earlier of their death, resignation, disqualification or removal. We have determined that Dr. Manuso and Mr. Thornton are independent directors under the marketplace rules of the Nasdaq Stock Market. There are no family relationships among any of our directors and executive officers.
| |
Audit
|
Nominating and Governance
|
Compensation
|
Michael J. McKenna Ph.D.
|
|
|
|
Dr. McKenna has served as our chairman since February 2008, as our chief executive officer from April 2004 to February 2008, and on our board of directors since April 2004. From April 2004 to April 2006, Dr. McKenna served as chairman of our board of directors. From September 1999 to March 2004, Dr. McKenna served as vice president of science and technology at A.M. Pappas & Associates, LLC, a life sciences venture development company. Previously, he owned and operated Pharmaceutical Consulting Services, advising the biopharmaceutical industry in drug development and drug safety. Prior to this he was Vice President, Drug Development at Parke Davis. Dr. McKenna also held numerous scientific and managerial positions in the toxicology laboratories of The Dow Chemical Company and Parke Davis. Dr. McKenna received a B.A. in English from St. John Fisher College and a Ph.D. in Toxicology from the University of Rochester School of Medicine and Dentistry.
|
|
John Lynch
|
|
|
|
Mr. Lynch has served as our chief executive officer since February 2008, as our chief operating officer since May 2005, as our managing director from April 2004 to May 2005, and on our board of directors since April 2005. From April 2003 to April 2004, Mr. Lynch was the chief executive officer of JML Healthcare. From April 1999 to April 2003, Mr. Lynch served as a divisional director of Abbott Laboratories Ltd., a global health care company. Previously, he held positions as senior business development manager, Abbott International USA; Division Director, Hospital Products and Nutritional Products Divisions, Abbott Laboratories, Ireland, and financial director, Abbott Laboratories, Ireland. Earlier in his career Mr. Lynch held financial positions with Bayer Diagnostics Limited and Ernst & Young. Mr. Lynch received a B.Comm. from University College Dublin. He is also a fellow of the Institute of Chartered Accountants in Ireland.
|
|
Anthony Carragher
|
|
|
|
|
Mr. Carragher has served on our board of directors since December 2004. Since January 2005, Mr. Carragher has served as the managing director of Complete Investment Solutions, and from July 2001 to December 2004, he was the investments manager of Irelandia Investments Limited. Mr. Carragher has served on the board of directors of Irelandia II Limited since July 2001, and on the board of directors of Growcorp Group Ltd. since October 2004. He received an A.C.A. from the Institute of Chartered Accountants in Ireland. He is also Chief Financial Officer to the One Foundation, a major Irish charitable organization.
|
|
Michael Donnelly
|
|
|
|
|
Professor Donnelly has served on our board of directors since April 2004. Professor Donnelly established Growcorp in January 1999. Prior to Growcorp, he was Vice President and General Manager of Cincinnati Sub Zero Inc., a medical products company in Cincinnati, Ohio, from 1996 to 1998, Vice President of IEP Group, Research Triangle Park, North Carolina from 1993 to 1996, Professor of Pediatrics, College of Medicine, University of Cincinnati, Ohio, and Director of Bioengineering Research at the Perinatal Research Institute, Cincinnati, Ohio from 1986 to 1996, Director of Research and Development from 1983 to 1986 and Director of Marketing from 1980 to 1983 with Air-Shields Inc. Professor Donnelly sits on the boards of Growcorp Group, Growcorp (GP), Gas Sensor Solutions, Fluorocap and Pharmatrin, Orakine, North Wall General Partners, Neutekbio, Irish Venture Capital Association and Irish Biotechnology Association and is the Managing Partner of the European Bioscience Fund.
|
|
Fintan Maher
|
|
|
|
|
Mr. Maher has served on our board of directors since April 2004. Since May 2005, he has served as the managing director of Northwall General Partners Ltd. From October 2004 to May 2005, Mr. Maher served as the managing director of Growcorp Group Ltd., an investment fund focused on life sciences companies. From June 1999 to September 2004, Mr. Maher was the investments manager of Irelandia Investments Ltd. Mr. Maher received a B.Comm. from University College Dublin. He is a member of the Society of Investment Analysts in Ireland, a member society of the CFA Institute.
|
James S.J. Manuso Ph.D.
|
|
|
|
|
Dr. Manuso has served on our board of directors since July 2006. Since January 2004, Dr. Manuso has served as the president and chief executive officer of SuperGen, Inc., which discovers, develops and commercializes hematology and oncology pharmaceuticals. Dr. Manuso has served on the board of directors of SuperGen, Inc. since February 2001, and as the chief executive officer-elect of SuperGen, Inc. from September 2003 to December 2003. Dr. Manuso is the co-founder and immediate past president and chief executive officer of Galenica Pharmaceuticals, Inc. Dr. Manuso co-founded and was general partner of PrimeTech Partners, a biotechnology venture management partnership, from 1998 to 2002, and managing general partner of The Channel Group LLC, an international life sciences corporate advisory firm. He was also president of Manuso, Alexander & Associates, Inc., management consultants and financial advisors to pharmaceutical and biotechnology companies. He currently serves on the board of directors of KineMed, Inc., a private company and Novelos Therapeutics, Inc. Previously, he served on the boards of Inflazyme Pharmaceuticals, Inc., Symbiontics, Inc. (now Zystor, Inc.), Quark Biotech, Inc., Galenica Pharmaceuticals, Inc., Supratek Pharma, Inc. and the greater San Francisco Bay Area Chapter of the Leukemia and Lymphoma Society. Dr. Manuso received a B.A. with honors in Economics and Chemistry from New York University, a Ph.D. in Experimental Psychophysiology from The Graduate Faculty of the New School University, a Certificate in Healthcare Management from Harvard Business School and an Executive M.B.A. from Columbia Business School.
|
|
Peter Thornton
|
|
|
|
|
Mr. Thornton has served on our board of directors since July 2006. In July 2007, Mr. Thornton was appointed senior vice president, head of product, technology and business development for Elan Drug Technologies. From September 2006 until July 2007, Mr. Thornton served as president and chief operating officer of Circ Pharma Limited, a specialty pharmaceutical product development company with a late stage pipeline focused on the development of novel formulations of existing drugs in the areas of cardiology and neurology. From June 2004 to September 2006, Mr. Thornton served as the senior vice president and chief financial officer of Antigenics, Inc., a Nasdaq-listed biotechnology company focused on cancer, infectious diseases and autoimmune disorders. From 1994 to 2004, Mr. Thornton held senior management positions in operations and finance with Elan Corporation, plc, most recently as senior vice president of business operations. Earlier, Mr. Thornton worked at the international accounting firm, KPMG, in Dublin and Paris. Mr. Thornton serves as a non-executive director of Antigenics, Inc. He earned a bachelor's degree in commerce from University College, Cork, Ireland, and is a fellow of the Institute of Chartered Accountants in Ireland.
|
|
Patrick O'Sullivan
|
|
|
|
Non- Executive Patrick O'Sullivan is a Pharmaceutical Business Consultant and current Chairman of the Board of Trustees of the Beacon Hospital. Prior to retirement in 2006, Mr. O'Sullivan was CEO of the Leo Pharma Group of Companies in Ireland and a Board Member of the parent company of the Leo Pharma Group in Denmark. He also served on the boards of The LEO Foundation, LEO Pharmaceuticals Ltd. UK and LEO Pharma SA France. For more than 20 years, Mr O'Sullivan was Chairman of the Pharma Industry team that negotiated the supply of research based pharmaceuticals to the Irish Health Services, on behalf of the Irish Pharmaceutical Healthcare Association Ltd. Mr. O'Sullivan holds Bachelor of Commerce and MBA degrees from University College Dublin, he is a registered pharmacist, member and honorary fellow of the Pharmaceutical Society of Ireland and a Knight of the Order of the Dannebrogbr />
|
